Join our daily newsletter At The Bell to receive exclusive market insights
Compumedics (ASX:CMP) has officially clocked a A$0.3M profit in the first half of FY26, officially bringing the company into profitability after a -$1.1M loss pcp.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Disclaimer: This content has been prepared as part of a partnership with CMP and is intended for informational purposes only.
That comes on the back of record sales orders hitting $35M (+6% vs pcp) and record revenue of $31M (+32% vs pcp) with the company’s flagship market-disrupting Magnetoencephalography (MEG) tech netting $6M of that.
The company recorded an operating cash inflow of A$1.8M (vs $2.1M outflow pcp) and reaffirmed on Wednesday its FY26 guidance for $70M revenues and $9M EBITDA.
Additional MEG sales are anticipated for 2HFY26 and the company reports a targeted focus on US sales is proving fruitful. At the same time, CMP is targeting a $2Mpa cost cutting initiative to support margins with “benefits expected” across the rest of CY2026.
CMP’s Somfit and Nexus 360 products both delivered sales growth vs pcp in the US and the Asia market continues to “perform very strongly overall” led by North Asian demand for neuroscanning technology.
Europe growth was stonger vs pcp and in ANZ momentum remains “broadly stable” with Somfit and Nexus 360 posting gains for the company there too, backed by subscription uptake.
Overall, CMP’s SaaS products saw a +56% expansion vs pcp.
CMP last traded at 33cps.
Join the discussion: See what HotCopper users are saying about CMP and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
